A review on treatment of high-risk neuroblastoma

Chinese Journal of Contemporary Pediatrics

Volumn 16, Issue 2, 2014, Pages 103-107

  Tang, Suo Qin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Chemotherapy, immunotharapy; Child; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC ALKALOID;

BIOLOGICAL THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; IMMUNOTHERAPY; NEUROBLASTOMA; REVIEW; STEM CELL TRANSPLANTATION;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA;

EID: 84898917263     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: 10.7499/j.issn.1008-8830.2014.02.001     Document Type: Review

References (11)

1. Mattano LA Jr, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction[J]. Cancer Res, 1992, 52(17): 4701-4705.
2. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies[J]. J Clin Oncol, 1996, 14(9): 2417-2426. (Pubitemid 26300106)
3. Vogelzang NJ, Benowitz SI, Adams S, et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology[J]. J Clin Oncol, 2012, 30(1): 88-109.
4. Castel V, Tovar JA, Costa E, et al. The role of surgery in stage IV neuroblastoma[J]. J Pediatr Surg, 2002, 37(11): 1574 -1578.
5. Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma[J]. Eur J Cancer, 2013. doi: 10.1016/j.ejca.2013.11.016. [Epub ahead of print].
6. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(10): 999-1008.
7. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma[J]. J Clin Oncol, 1998, 16(6): 2169-2180. (Pubitemid 28265055)
8. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients withneuroblastoma[J]. Eur J Cancer, 1995, 31A(2): 261-267.
9. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
10. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy[J]. J Pediatr Hematol Oncol, 2013, 35(5): 337-347.
11. Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems[J]. Bone Marrow Transplant, 2014. doi: 10.1038/bmt.2013.218. [Epub ahead of print].